Latest Period
Q1 2026
Security Snapshot
Coya Therapeutics, Inc. - Common Stock, $0.0001 par value per share (COYA) Institutional Ownership
CUSIP: 22407B108
13F Institutional Holders and Ownership History from Q4 2022 to Q1 2026
Institutions Reporting
56
Shares (Excl. Options)
8,091,703
Price
$3.94
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- COYA on Nasdaq
- Shares outstanding
- 23,430,175
- Price per share
- $4.11
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 8,091,703
- Total reported value
- $31,887,752
- % of total 13F portfolios
- 0%
- Share change
- +100,461
- Value change
- -$1,299,567
- Number of holders
- 56
- Price from insider filings
- $4.11
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- COYA - Coya Therapeutics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 22407B108.
- 56 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 58 to 56 between Q4 2025 and Q1 2026.
- Reported value moved from $46,046,406 to $31,887,752.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 56 institutions filings for Q1 2026.
Investment Quick Answers
What is CUSIP 22407B108?
CUSIP 22407B108 identifies COYA - Coya Therapeutics, Inc. - Common Stock, $0.0001 par value per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q1 2026 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 22407B108:
Significant Owners of Coya Therapeutics, Inc. - Common Stock, $0.0001 par value per share (COYA) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Dr. Reddy's Laboratories, Inc. | 9.7% | $10,727,271 | 2,272,727 | Dr. Reddy's Laboratories, Inc. | 30 Jan 2026 | |||
| DME Capital Management, LP | 9.9% | $10,783,903 | 1,651,440 | DME Advisors GP, L.L.C. | 31 Dec 2024 | |||
| HIRSCHMAN ORIN | 5.3% | -34% | $6,427,392 | -$1,309,338 | 1,108,171 | -17% | Orin Hirschman | 31 Dec 2025 |
| VANGUARD GROUP INC | 4.3% | $5,215,012 | 899,140 | The Vanguard Group | 31 Dec 2025 |
As of 31 Mar 2026, 56 institutional investors reported holding 8,091,703 shares of Coya Therapeutics, Inc. - Common Stock, $0.0001 par value per share (COYA). This represents 35% of the company’s total 23,430,175 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Coya Therapeutics, Inc. - Common Stock, $0.0001 par value per share (COYA) together control 33% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| DME Capital Management, LP | 10% | 2,335,540 | +15% | 0.29% | $9,202,027 |
| AIGH Capital Management LLC | 4.2% | 975,404 | 0% | 0.79% | $3,843,092 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.6% | 844,913 | 0% | 0% | $3,328,957 |
| Alyeska Investment Group, L.P. | 3.4% | 800,000 | 0% | 0.01% | $3,152,000 |
| Prosight Management, LP | 1.8% | 420,360 | 0.27% | $1,656,218 | |
| CM Management, LLC | 1.6% | 375,000 | +7.1% | 1.2% | $1,477,500 |
| PRIVATE MANAGEMENT GROUP INC | 1.6% | 369,096 | +32% | 0.04% | $1,454,238 |
| GEODE CAPITAL MANAGEMENT, LLC | 1% | 233,402 | +18% | 0% | $919,783 |
| MARSHALL WACE, LLP | 0.96% | 225,792 | +0.19% | 0% | $889,621 |
| VANGUARD FIDUCIARY TRUST CO | 0.6% | 139,886 | 0% | 0% | $551,151 |
| RENAISSANCE TECHNOLOGIES LLC | 0.44% | 103,964 | +55% | 0% | $409,618 |
| PRELUDE CAPITAL MANAGEMENT, LLC | 0.43% | 101,330 | +94% | 0.03% | $399,240 |
| JBF Capital, Inc. | 0.43% | 100,006 | 0% | 0.06% | $394,024 |
| DIMENSIONAL FUND ADVISORS LP | 0.41% | 95,919 | +205% | 0% | $377,251 |
| MORGAN STANLEY | 0.37% | 85,700 | +61% | 0% | $337,658 |
| BlackRock, Inc. | 0.35% | 82,769 | +4.6% | 0% | $326,110 |
| STATE STREET CORP | 0.34% | 79,813 | +15% | 0% | $314,463 |
| 683 Capital Management, LLC | 0.3% | 70,000 | -13% | 0.03% | $275,800 |
| XTX Topco Ltd | 0.2% | 47,338 | +43% | 0% | $186,512 |
| JONES FINANCIAL COMPANIES LLLP | 0.19% | 44,960 | +786% | 0% | $178,042 |
| Squarepoint Ops LLC | 0.17% | 40,465 | -38% | 0% | $159,432 |
| NORTHERN TRUST CORP | 0.17% | 40,418 | 0% | 0% | $159,247 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.17% | 39,316 | -69% | 0% | $154,905 |
| Long Corridor Asset Management Ltd | 0.17% | 38,766 | 0% | 0.04% | $152,738 |
| UBS Group AG | 0.16% | 38,564 | +10% | 0% | $151,942 |
Institutional Holders of Coya Therapeutics, Inc. - Common Stock, $0.0001 par value per share (COYA) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 8,091,703 | $31,887,752 | -$1,299,567 | $3.94 | 56 |
| 2025 Q4 | 7,939,025 | $46,046,406 | +$18,480,971 | $5.80 | 58 |
| 2025 Q3 | 4,755,804 | $27,110,326 | +$1,543,439 | $5.70 | 35 |
| 2025 Q2 | 4,484,686 | $25,787,239 | -$1,022,977 | $5.75 | 33 |
| 2025 Q1 | 4,662,591 | $30,167,676 | +$1,480,613 | $6.47 | 26 |
| 2024 Q4 | 4,444,580 | $25,467,940 | +$6,454,839 | $5.73 | 26 |
| 2024 Q3 | 3,315,161 | $21,385,210 | +$304,078 | $6.45 | 19 |
| 2024 Q2 | 3,268,292 | $19,805,900 | -$932,467 | $6.06 | 19 |
| 2024 Q1 | 3,339,060 | $33,123,748 | +$5,311,359 | $9.92 | 19 |
| 2023 Q4 | 2,822,037 | $20,644,859 | +$10,288,077 | $7.41 | 20 |
| 2023 Q3 | 1,416,355 | $5,449,280 | +$229,488 | $3.84 | 14 |
| 2023 Q2 | 1,351,642 | $5,500,530 | +$1,016,457 | $4.07 | 13 |
| 2023 Q1 | 1,101,849 | $4,368,596 | +$41,079 | $3.97 | 7 |
| 2022 Q4 | 1,091,417 | $5,156,354 | +$5,156,354 | $4.74 | 4 |